Question Everything. See who's reporting it.

FDA Approves First Targeted Therapy for Pancreatic Cancer

Source: Forbes

The story in brief

The FDA has approved daraxonrasib, the first targeted therapy for pancreatic ductal adenocarcinoma, after impressive trial results showed a median survival of 13.2 months compared to 6.7 months with chemotherapy. Over 90% of PDAC patients have RAS mutations, making them potential candidates. The approval was based on data presented at the American Society of Clinical Oncology meeting, where over 9,000 attendees gave a standing ovation.

5 outletsSee what the other 4 outlets said

NEWXFree on Android and iPhone. Open in NEWX